Last reviewed · How we verify
SHC014748M treatment — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SHC014748M treatment (SHC014748M treatment) — Nanjing Sanhome Pharmaceutical, Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SHC014748M treatment TARGET | SHC014748M treatment | Nanjing Sanhome Pharmaceutical, Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SHC014748M treatment CI watch — RSS
- SHC014748M treatment CI watch — Atom
- SHC014748M treatment CI watch — JSON
- SHC014748M treatment alone — RSS
Cite this brief
Drug Landscape (2026). SHC014748M treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/shc014748m-treatment. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab